ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

CYTO Altamira Therapeutics Ltd

1.58
-0.06 (-3.66%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Altamira Therapeutics Ltd CYTO 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.06 -3.66% 1.58 08:30:15
개장가 저가 고가 종가 전일 종가
1.62 1.60 1.66 1.64 1.64
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
01/05/202421:47GLOBEAltamira Therapeutics Announces Filing of Provisional Patent..
24/04/202421:47GLOBEAltamira Therapeutics Announces Publication of Positive..
10/04/202421:00GLOBEAltamira Therapeutics Provides Business Update, Reports Full..
04/04/202421:45GLOBEAltamira Therapeutics to Host Full Year 2023 Financial..
25/03/202421:47GLOBEAltamira Therapeutics Announces Collaboration with..
07/02/202422:47GLOBEAltamira Therapeutics’ Peptide-Based Delivery Platform Shown..
24/01/202422:47GLOBEAltamira Therapeutics Files Second Provisional Patent..
23/01/202407:02EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
22/01/202414:15EDGAR2Form EFFECT - Notice of Effectiveness
20/01/202406:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/01/202406:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/01/202406:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/01/202407:02EDGAR2Form F-3 - Registration statement by foreign private issuers
08/01/202422:47GLOBEAltamira Therapeutics to Present at 3rd Annual mRNA-Based..
29/12/202322:47GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
11/12/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202322:00GLOBEAltamira Therapeutics Provides Investor and Business Update
08/12/202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/12/202302:54GLOBEAltamira Therapeutics to Host Investor & Business Update..
30/11/202300:20GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
23/11/202306:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202323:04GLOBEAltamira Therapeutics Announces Partial Spin-Off of Bentrio®..
10/11/202322:47GLOBEAltamira Therapeutics Announces European Patent Office..
01/11/202305:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/09/202321:47GLOBEAltamira Therapeutics Reports Additional Significant..
12/09/202320:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/09/202320:30GLOBEAltamira Therapeutics Provides Business Update and First..
06/09/202321:47GLOBEAltamira Therapeutics to Host First Half 2023 Financial..
23/08/202321:47GLOBEAltamira Therapeutics to Present at H.C. Wainwright 25th..
21/08/202320:31EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
28/07/202320:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/07/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/07/202321:47GLOBEAltamira Therapeutics and Pharma Nordic Collaborate for..
17/07/202321:47GLOBEAltamira Therapeutics Announces Publication of Positive..
11/07/202321:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/07/202305:14EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05/07/202321:47GLOBEAltamira Therapeutics Announces Collaboration with Heqet..
30/06/202319:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

최근 히스토리

Delayed Upgrade Clock